Dare Bioscience Investor Presentation Deck
February 2023, 54 slides
  1. Dare Bioscience
  2. Related Decks
  3. Investor Presentation Decks
dar dar in it means to give in it means to be bold dare a a dare | Dare Bioscience
maul teeter | Dare Bioscience
women health is our sole focus women health is our sole focus | Dare Bioscience
women health is our sole focus women health an efficient investment thesis approximately of research is invested in female specific conditions beyond oncology women health conditions outside of oncology comprise less than of the current pipeline we believe investment in women health will be efficient and disproportionately women health products make up of total blockbuster products while contributing to of total blockbuster sales women control of purchasing decisions a | Dare Bioscience
women health compelling markets where innovation matters contraception vaginal health reproductive menopause and sexual health what are the next big ideas fertility | Dare Bioscience
dar portfolio the big ideas contraception vaginal health reproductive menopause and sexual health fertility dare | Dare Bioscience
dar a compelling opportunity upcoming program milestones | Dare Bioscience
advancing products women want the portfolio snapshot | Dare Bioscience
approved phosphate vaginal gel | Dare Bioscience
advancing products women want late stage programs cream dare | Dare Bioscience
advancing products women want phase and preclinical phase clinical phase dare | Dare Bioscience
dar advancing products women want dare multiple upcoming a potential first line or program milestones first in class product anticipated opportunity demonstrated success in clinical ail regulatory affairs corporate interest as evidenced | Dare Bioscience
experienced management board of directors we are delivering innovation by daring to be different mid technologies baxter | Dare Bioscience
dar financial highlights non dilutive cash received snapshot cash and equivalents common shares warrants funding sources | Dare Bioscience
dar working to accelerate innovation in women health upcoming program milestones dare | Dare Bioscience
dare phosphate vaginal gel gel for bacterial approved for the treatment of bacterial the most common vaginal condition in women of reproductive age one time intravaginal administration commercialization collaborator approved fast track and priority review designations i organon | Dare Bioscience
clinical issue limitations with current standards of care target product profile bacterial dar innovation phosphate vaginal gel | Dare Bioscience
overview she toe phosphate vaginal gel is a antibacterial indicated for the treatment of bacterial in female patients years of age and older this marks the first approved product in dar portfolio of potential first in category development candidates first commercial sale anticipated in the | Dare Bioscience
commercial license agreement with organon organon | Dare Bioscience
important safety information indication dosage administration contraindications warnings precautions adverse reactions drug interactions | Dare Bioscience
use in special populations special populations special populations special populations | Dare Bioscience
investigational potential first in category hormone free monthly birth control commercialization collaborator phase development collaborator | Dare Bioscience
contraception large market opportunity | Dare Bioscience
potential market opportunity | Dare Bioscience
contraception what missing from current hormone free options | Dare Bioscience
investigational hormone free monthly contraceptive efficacy hormone free convenience favorable side effect profile easily manage fertility safety similar to a diaphragm environments | Dare Bioscience
commercial license agreement with | Dare Bioscience
collaborative research agreement with | Dare Bioscience
regulatory strategy strategy | Dare Bioscience
cream potential first in category treatment for female sexual arousal disorder which has no approved therapies novel cream formulation of to treat utilizing active ingredient in | Dare Bioscience
the clinical issue female sexual arousal disorder is characterized the condition should be distinguished primarily by inability to attain or maintain sufficient genital from a general loss of interest in sexual arousal during sexual activity and of female sexual function activity and from other sexual disorders is most analogous to erectile dysfunction in dysfunctions such as orgasmic disorder men and hypoactive sexual desire disorder which is characterized as lack or absence of sexual fantasies and desire for sexual activity for some period of time | Dare Bioscience
what is the incidence | Dare Bioscience
cream product profile topically administered investigational cream is a inhibitor utilized in medications for men product peaked at billion in sales in designed to increase local blood flow to provide improvement in genital arousal response applied topically avoiding hepatic first pass metabolism response resulting in lower systemic exposure potentially resulting in reduced side effects oral including given similarities between and the active ingredient in may improve genital arousal response and overall sexual experience for women as it does in men there are no approved treatments for | Dare Bioscience
cream phase ongoing phase clinical study aims to evaluate cream placebo over weeks of dosing following both a non drug and placebo run in period compares cream placebo used in patients home setting primary patient reported outcome pro instruments to measure improvement in localized genital sensations of arousal and reduction in related distress several exploratory efficacy will be measured and could become additional measurements of efficacy in a future phase program topline data of phase respond study targeted for | Dare Bioscience
oral provided a compelling proof of concept for | Dare Bioscience
cream phase and phase a study results parameter | Dare Bioscience
cream thermography study results | Dare Bioscience
dare potential first in category day intravaginal ring combination identical estradiol and identical progesterone for hormone therapy for treatment of vasomotor symptoms due to menopause there are no approved options with both hormones in one monthly | Dare Bioscience
intravaginal ring technology highlights the vaginal route of drug administration our technology design features vaginal drug delivery offers many potential advantages due to large surface area dense network of blood vessels and high elasticity due to presence of smooth muscle fibers recognized advantages include comparable ease of administration and ability to bypass hepatic first pass metabolism sustained drug delivery variable dosing and duration solid ethylene vinyl acetate polymer matrix that can contain and release one or several active drugs no need for membrane or reservoir to contain active drug or control the release | Dare Bioscience
dare over women in approaching or in menopause menopause | Dare Bioscience
dare a | Dare Bioscience
dare regulatory strategy following clinical development dar intends to leverage the existing safety and efficacy data on the active ingredients in dare estradiol and progesterone to utilize the food and drug administration pathway to obtain marketing approval of dare in the dar intends to seek approval of dare for the treatment of moderate to severe due to menopause in women with intact uteri based on communications with the and the topline data from the dare phase study dar believes approval of dare for that indication is achievable via the pathway supported by a single placebo controlled phase clinical trial of dare and a scientifically justified bridge via a relative trial between dare and the selected listed estradiol and progesterone drugs ongoing activities to support progressing directly into a single phase study to support registration include manufacturing and non clinical studies to support the submission and the planned opening phase study dare strategy | Dare Bioscience
phase and preclinical programs new investigational prescription drug delivery options for women | Dare Bioscience
advancing products women want phase and preclinical phase clinical phase dare | Dare Bioscience
dare and dare dare i | Dare Bioscience
dare | Dare Bioscience
dare proof of concept dare | Dare Bioscience
dare phase study dare | Dare Bioscience
dare market research suggests that the global market for dysmenorrhea treatment is estimated to be valued at billion and that the size of this market is expected to increase to billion by the year | Dare Bioscience
women in are in the reproductive health and contraception market segment segment | Dare Bioscience
dare through june june define develop and evaluate the product concept grant of to explore device insertion removal in | Dare Bioscience
dare bacterial and vulvovaginal represent the two most common vaginal infections in the united states leading to over million treatment visits per year | Dare Bioscience
dare grant from the bill gates foundation for to support activities related to development of a vaginal thermosetting gel formulation for the delivery of live that can be reconstituted at the point of care | Dare Bioscience
daring to be different and advancing products women want dare to be bold dar | Dare Bioscience
See More
Dare Bioscience
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Delivery
Recent decks by Dare Bioscience
Results
November 2023
Investor Presentation
August 2023
Investor Presentation
July 2023
Investor Presentation
October 2022
See all presentations by Dare Bioscience (5 decks)
Related decks
RenovoRx
IPO
August 2021
Taysha
IPO
September 2020
MindMed
Investor Day
June 2023
Matinas BioPharma
Investor Presentation
August 2023
UpHealth
SPAC
November 2020
Babylon
Investor Presentation
September 2021
Matinas BioPharma
Investor Presentation
January 2024
Matinas BioPharma
Investor Presentation
February 2024
Recent decks by Dare Bioscience
See all presentations (5 decks)
Results
November 2023
Investor Presentation
August 2023
Investor Presentation
July 2023
Investor Presentation
October 2022
RenovoRx
IPO
August 2021
Taysha
IPO
September 2020
MindMed
Investor Day
June 2023
Matinas BioPharma
Investor Presentation
August 2023
UpHealth
SPAC
November 2020
Babylon
Investor Presentation
September 2021
Matinas BioPharma
Investor Presentation
January 2024
Matinas BioPharma
Investor Presentation
February 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io